| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2013: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Outline of Final Research Achievements |
Canine malignant melanoma is one of the intractable diseases. In order to develop the new treatment, we focused the CD3-activated T cell (CAT) therapy. To improve it for increasing the specificity for melanoma, we used DH82, melanoma-associated peptides, and anti Gpnmb antibody. However, these combinations did not promote the proliferation of lymphocytes, and not enhance the anti tumor activity of CAT, either. On the other hand, canine melanoma cells (CMM2) was administered subcutaneously into nu/nu mice, and simultaneously injected with CAT or CAT pulsed by melanoma-associated peptides. Then, CAT or CAT pulsed by peptides inoculation caused significantly lower tumor growth than saline’s one. In conclusion, CAT certainly showed an anti-tumor activity in nu/nu mice, but further studies were necessary for more improvement of CAT therapy.
|
